Why Merck Missed the Mark
Why Merck Missed the Mark S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold
Why Merck Missed the Mark S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold
Biotech: Teva’s Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market
Get new actionable insights and updates from BiotechBlog